

WOCKHARDT LIMITED

UNAUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2009



(Rs. In Million)

PARTICULARS	QUARTER ENDED 30/6/2009	% TO SALES	QUARTER ENDED 30/6/2008	% TO SALES	GROWTH %	SIX MONTHS ENDED 30/6/2009	% TO SALES	SIX MONTHS ENDED 30/6/2008	% TO SALES	GROWTH %	YEAR ENDED 31/12/2008	% TO SALES
Income from Operations	9,542	100.0	9,103	100.0	4.8	18,174	100.0	17,315	100.0	5.0	35,912	100.0
Total Expenditure	7,863	82.4	6,990	76.8	12.5	14,680	80.8	13,173	76.1	11.4	27,944	77.8
a) (Increase)/Decrease in stock	335	3.5	(443)	(4.9)	(175.6)	645	3.5	(1,210)	(7.0)	(153.3)	(297)	(0.8)
b) Consumption of raw material	2,476	25.9	1,923	21.1	28.8	4,049	22.3	3,813	22.0	6.2	7,912	22.0
c) Purchase of Finished Goods	1,549	16.2	1,672	18.4	(7.4)	3,135	17.2	3,178	18.4	(1.4)	5,847	16.3
Material Consumption	4,360	45.7	3,152	34.6	38.3	7,829	43.1	5,781	33.4	35.4	13,462	37.5
d) Staff Cost	1,460	15.3	1,615	17.7	(9.6)	2,940	16.2	3,160	18.3	(7.0)	6,074	16.9
e) R & D expenditure	139	1.5	218	2.4	(36.2)	286	1.6	361	2.1	(20.8)	513	1.4
f) Other expenditure	1,904	20.0	2,005	22.0	(5.0)	3,625	19.9	3,871	22.4	(6.4)	7,895	22.0
Other Expenditure	3,503	36.7	3,838	42.2	(8.7)	6,851	37.7	7,392	42.7	(7.3)	14,482	40.3
Gross Profit before Interest, Depreciation & Taxation	1,679	17.6	2,113	23.2	(20.5)	3,494	19.2	4,142	23.9	(15.6)	7,968	22.2
Interest/ Financing Cost												
(a) Interest	779	8.2	641	7.0	21.5	1,731	9.5	1,203	6.9	43.9	2,590	7.2
(b) Income/(Expense) due to Exchange Rate Fluctuation	264		(90)			(60)		(415)			(9)	
(c) Premium on FCCB	88		-			175		-			1,295	
Gross Profit after Interest but before Depreciation & Taxation	1,076	11.3	1,382	15.2	(22.1)	1,528	8.4	2,524	14.6	(39.5)	4,074	11.3
Depreciation	303	3.2	252	2.8	20.2	613	3.4	493	2.8	24.3	1,130	3.1
Profit after Interest & depreciation	773	8.1	1,130	12.4	(31.6)	915	5.0	2,031	11.7	(54.9)	2,944	8.2
Other Income	84	-	68	-	-	187	-	143	-	-	356	-
Exceptional Item Profit/(Loss)	(2,646)		190			(2,847)		(175)			(5,810)	
Profit/(Loss) before Tax	(1,789)	(18.7)	1,388	15.2	(228.9)	(1,745)	(9.6)	1,999	11.5	(187.3)	(2,510)	(7.0)
Provision for Taxation	69		184			121		294			237	
Fringe Benefit Tax	0		9			6		18			39	
Deferred Taxation	35		159			119		159			(1,192)	
Profit/ (Loss) After Tax	(1,893)	(19.8)	1,036		(282.7)	(1,991)	(11.0)	1,528		(230.3)	(1,594)	
Add: Share of Profit/ (Loss) from Associates	(6)		23			(10)		39			205	
Net Profit/(Loss)	(1,899)	(19.9)	1,059	11.6	(279.3)	(2,001)	(11.0)	1,567	9.0	(227.7)	(1,389)	(3.9)
Paid-up Equity Share Capital (Rs 5/-each)	547		547		-	547		547		-	547	
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-		-	-		-		-	9,630	
Earning Per Share												
Basic Earning Per Share (Rs)	(17.35)		9.68			(18.28)		14.32			(12.69)	
Diluted Earning Per Share (Rs)	(17.35)		9.68			(18.28)		14.32			(12.69)	

Public Shareholding							
- Number of Shares	28,193,643	28,075,803		28,193,646	28,075,803		28,102,803
- Percentage to Paid-up Capital	25.76%	25.66%		25.76%	25.66%		25.68%
Promoters and promoter group shareholding							
a) Pledged/ Encumbered							
- Number of shares	57,878,000			57,878,000			69,280,667
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	71.82%			71.82%			85.97%
-Percentage of shares (as a % of the total share capital of the Company)	52.89%			52.89%			63.31%
b) Non-encumbered							
- Number of shares	22,707,382			22,707,382			11,304,715
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	28.18%			28.18%			14.03%
-Percentage of shares (as a % of the total share capital of the Company)	20.75%			20.75%			10.33%

Notes To Consolidated Financials:-

- 1) The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on July 30, 2009
- 2) The outstanding liabilities of the Company are being restructured under the aegis of Corporate Debt Restructuring (CDR). The Empowered Group of CDR has approved the restructuring proposal subject to execution of Master Restructuring Agreement (MRA) and other necessary documents. The CDR scheme comprehensively covers the crystallised derivative/ hedging liabilities which were reported earlier.
- 3) Pursuant to the announcement on 'Accounting for Derivatives' issued by the Institute of Chartered Accountants of India in March 2008, the Company has accounted Mark-to-Market (MTM) losses aggregating Rs. 2,553 million for the quarter ended June 30, 2009 based on independent valuers report. The same has been treated as Exceptional Item. The Company has entered into Hedging Instruments, which are long term in nature to reduce interest cost/ Currency risk for the loans, export receivables and import payables, which the Company has taken in past and is outstanding as of June 30, 2009. As per the Risk Management Policy, the Company is hedging the interest/ currency risk the long term loans, export receivables and import payables. The Company does not hold or issue derivative financial instruments for trading or speculative purposes.
- 4) In the month of October 2004, the Company had issued 110,000 Zero Coupon foreign currency convertible bonds of USD 1,000 each. The Bonds are considered as monetary liability. The Bonds are redeemable on maturity date at 129.578 percent of its principal amount, only if there is no conversion of bonds on or before September 25, 2009. The Company is evaluating various options for restructuring the debts. The FCCB including the premium payable will be part of the restructuring exercise.
- 5) The Company has entered into definitive agreement on June 26, 2009 for divestment of the Animal Healthcare Business and on July 28, 2009 for divestment of the Nutrition Business. As the said transactions are subject to customary closing conditions and various approvals, the impact of these transactions will be accounted during the quarter in which the said transactions are closed.
- 6) As on April 1, 2009 the Company had no investors complaints pending. During the quarter the Company has not received any complaints. Accordingly, no complaints are pending as on June 30, 2009.
- 7) The Company is exclusively into Pharmaceutical business Segment.
- 8) Previous period figures have been recast/ re-classified to conform to the current period's presentation.